Article
Physiology
Xinyi Gao, Zhike Xu, Chenghan Chen, Pengfei Hao, Feng He, Xiwen Zhang
Summary: Ventricular assist devices (VAD) are widely used in the treatment of end-stage heart failure patients to improve circulatory dysfunction. A multi-Domain model of the left ventricular coupled axial flow artificial heart was used to study its impact on aortic hemodynamics. The results showed that LVAD significantly increased vorticity intensity compared to patients' conditions and approached that of a healthy ventricle. During LVAD surgery, high-speed blood flow was mainly concentrated near the lining of the ascending aorta.
FRONTIERS IN PHYSIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
E. Wilson Grandin, Gaurav Gulati, Jose Nunez, Kevin Kennedy, J. Eduardo Rame, Pavan Atluri, Francis D. Pagani, James K. Kirklin, Robert L. Kormos, Jeffrey Teuteberg, Michael S. Kiernan
Summary: Adult CF-LVAD patients receiving early PDE5i showed similar rates of late right heart failure, mortality and major bleeding compared to those who did not receive early PDE5i.
CIRCULATION-HEART FAILURE
(2022)
Article
Cardiac & Cardiovascular Systems
Rashmi Jain, Lauren K. Truby, Veli K. Topkara
Summary: Residual MR is associated with worse clinical outcomes in patients supported by LVAD, and strategies to minimize MR should be considered in LVAD patients with residual MR.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2022)
Article
Cardiac & Cardiovascular Systems
Anubodh S. Varshney, Ersilia M. DeFilippis, Jennifer A. Cowger, Ivan Netuka, Sean P. Pinney, Michael M. Givertz
Summary: With the increasing prevalence of advanced heart failure, treatment options such as heart transplantation and LVAD support have shown to improve quality of life and extend survival. Recent advancements, including the use of HeartMate 3 in clinical practice and revisions to the organ allocation system, have led to better management of LVAD-related complications. Although contemporary LVAD recipients have higher illness severity preoperatively, they have higher survival rates and lower adverse event rates compared to previous eras. However, challenges such as bleeding, infection, neurologic events, and right ventricular failure still limit the wider implementation of LVAD support. Ongoing efforts to optimize management of current LVAD devices and develop next-generation devices are expected to further enhance outcomes for patients with advanced heart failure.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Review
Medicine, General & Internal
Alessia Gambaro, Gianmarco Lombardi, Francesco Onorati, Leonardo Gottin, Flavio Luciano Ribichini
Summary: LVAD implantation has complex effects on the kidneys, particularly regarding renal function. Creatinine-based eGFR formulas help in assessing patient prognosis, while deterioration in renal function in LVAD patients negatively impacts outcomes.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Cardiac & Cardiovascular Systems
Dominic Emerson, Joanna Chikwe, Pedro Catarino, Mohamed Hassanein, Luqin Deng, Ryan S. Cantor, Amy Roach, Robert Cole, Fardad Esmailian, Jon Kobashigawa, Jaime Moriguchi, James K. Kirklin
Summary: In contemporary practice, elderly patients receiving LVADs showed improved survival, increased functional capacity, enhanced quality of life, and fewer complications compared with younger patients.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Engineering, Biomedical
Teruhiko Imamura, Nikhil Narang, Stephanie Besser, Daniel Rodgers, Pamela Combs, Umar Siddiqi, Corinne Stonebraker, Valluvan Jeevanandam
Summary: Anemia is prevalent in LVAD patients and is associated with a higher risk of heart failure and hemocompatibility-related adverse events. Further investigation is needed to determine the optimal threshold for therapeutic intervention in post-LVAD anemia.
Review
Cardiac & Cardiovascular Systems
Claudio A. Bravo, Andrew G. Navarro, Karanpreet K. Dhaliwal, Maziar Khorsandi, Jeffrey E. Keenan, Parvathi Mudigonda, Kevin D. O'Brien, Claudius Mahr
Summary: Left ventricular assist device (LVAD) therapy is a life-saving option for patients with advanced heart failure who do not respond to medical treatment. However, a significant percentage of LVAD patients develop right heart failure (RHF), which is associated with poor outcomes. The mechanisms of RHF are complex, involving patient factors, surgical factors, and hemodynamic factors. Despite advances in surgical techniques and LVAD technology, RHF remains a major cause of morbidity and mortality among LVAD patients. Current medical therapies for RHF are limited, and cardiac transplantation or supportive management are the only options for these patients. Efforts to predict the risk of RHF in LVAD patients have been challenging, with varying definitions of RHF in different studies. Additionally, most research in this field has focused on early-onset RHF, while late-onset RHF is increasingly recognized as a significant problem. This review aims to describe the unique physiology of the right ventricle and the changes caused by LVADs that may contribute to both early- and late-onset RHF. The available treatments for RHF, including mechanical circulatory support and medical therapies, will also be analyzed.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Robert N. Sladen, Mark A. Shulman, Azka Javaid, Carol Hodgson, Paul S. Myles, David Mcgiffin, Shunichi Nakagawa, Amrin M. Amlani, Jonathan Hupf, Koji Takeda, Yoshifumi Naka, Hiroo Takayama, Peter Bergin, Mark R. Buckland, Melana Yozefpolskaya, Paolo C. Colombo
Summary: There is a lack of data on depression, anxiety, and post-traumatic stress disorder after left ventricular assist device (LVAD) implantation. This observational study found that one-third of discharged LVAD patients reported impaired function, health-related quality of life, and psychological issues.
JOURNAL OF CARDIAC FAILURE
(2022)
Article
Cardiac & Cardiovascular Systems
Ofer Havakuk, Aviram Hochstadt, Sapir Sadon, Michal Laurel Perl, Ben Sadeh, Assi Milwidsky, Orly Ran Sapir, Yoav Granot, Lior Lupu, Erez Levi, Ariel Farkash, Yanai Ben Gal, Shmuel Banai, Yan Topilsky
Summary: This study demonstrates that long-term stabilization of patients entering a left ventricular assist device (LVAD) program is possible with the use of aggressive conservative therapy.
Article
Cardiac & Cardiovascular Systems
Maryam Ajmal, Aisha Ajmal, Maryam Rizvi, Umar Salim, Lei Huang
Summary: This study aimed to investigate the changes in myocardial gene expression profile after LVAD implantation and their molecular biological significance. The results showed that inflammatory signaling pathway is crucial for the pathophysiology after LVAD implantation and chemokines mediate cardiac inflammatory response and tissue remodeling through GPCR-ligand binding.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Andrew N. Rosenbaum, Bradley W. Ternus, Siddharth Pahwa, John M. Stulak, Alfredo L. Clavell, Sarah D. Schettle, Atta Behfar, Jacob C. Jentzer
Summary: In patients undergoing left ventricular assist device implantation, right ventricular stroke work index, right heart catheterization, cardiopulmonary bypass time, and ultrafiltration are strongly associated with incident INT-LD and decreased 1-year survival. Optimization of these factors may reduce the risk of liver dysfunction but further validation is needed.
ANNALS OF THORACIC SURGERY
(2021)
Article
Cardiac & Cardiovascular Systems
Teruhiko Imamura, Koichiro Kinugawa, Takashi Nishimura, Koichi Toda, Yoshikatsu Saiki, Hiroshi Niinami, Shinichi Nunoda, Goro Matsumiya, Motonobu Nishimura, Hirokuni Arai, Masanobu Yanase, Norihide Fukushima, Takeshi Nakatani, Akira Shiose, Ikuko Shibasaki, Yasushi Sakata, Minoru Ono
Summary: Recently, DT was approved in Japan, allowing patients ineligible for heart transplantation to receive LVADs. However, the best risk score to select optimal candidates for DT in the Japanese population is still undecided. We constructed the J-MACS risk score using large-scale multicenter Japanese data to estimate the 3-year mortality rate after durable LVAD implantation.
CIRCULATION JOURNAL
(2023)
Article
Medicine, General & Internal
Alexander A. Brescia, Tessa M. F. Watt, Francis D. Pagani, Thomas M. Cascino, Min Zhang, Jeffrey S. McCullough, Supriya Shore, Donald S. Likosky, Keith D. Aaronson, Michael P. Thompson
Summary: The study found that a significant proportion of LVAD recipients are ineligible for clinical trials, and that mortality rates are higher among those who are ineligible compared to those who are eligible. The results suggest that criteria for clinical trial eligibility should be more reflective of real-world experience.
Article
Cardiac & Cardiovascular Systems
Osnat Itzhaki Ben Zadok, Binyamin Ben-Avraham, Tiny Jaarsma, Aviv Shaul, Yoav Hammer, Yaron D. Barac, Israel Mats, Orit Eldar, Miriam Abuhazira, Vicky Yaari, Dmitry Gulobov, Mastwal Mulu, Dan Aravot, Ran Kornowski, Tuvia Ben-Gal
Summary: This study found that short-term and long-term LVAD-supported patients experienced impaired health-related quality of life and sexual function, but reported improvements in social interactions and independence.
Article
Endocrinology & Metabolism
Niels H. Brandt-Jacobsen, Mikkel Jurgens, Philip Hasbak, Peter Gaede, Peter Rossing, Jon J. Rasmussen, Camillla Fuchs Andersen, Julie L. Forman, Jens Faber, Silvio E. Inzucchi, Finn Gustafsson, Morten Schou, Caroline Kistorp
Summary: This study investigated the effects of short-term empagliflozin therapy on cardiac adipose tissue accumulation in patients with type 2 diabetes. The results showed that empagliflozin can reduce cardiac adipose tissue accumulation and improve weight and glucose metabolism. However, no correlation was observed between changes in cardiac volumetrics and cardiac adipose tissue accumulation.
DIABETES OBESITY & METABOLISM
(2023)
Article
Cardiac & Cardiovascular Systems
Sam Aiyad Ali, Mads Ersboll, Naja Emborg Vinding, Jawad Haider Butt, Rasmus Rorth, Christian Selmer, Lucas Malta Westergaard, Ulrik Madvig Mogensen, Peter E. Weeke, Christian Jons, Finn Gustafsson, Emil Fosbol, Lars Kober, Soren Lund Kristensen
Summary: The incidence of thyroid dysfunction is around 5% in patients initiating amiodarone treatment, with a slightly higher incidence in those with heart failure. There is a dose-response relationship between the accumulated dose of amiodarone and the cumulative incidence of thyroid dysfunction.
Article
Cardiac & Cardiovascular Systems
Camilla Fuchs Andersen, Massar Omar, Andreas Glenthoj, Daniel El Fassi, Holger J. Moller, Jorgen A. Lindholm Kurtzhals, Bjarne Styrishave, Caroline Kistorp, Christian Tuxen, Mikael K. Poulsen, Jens Faber, Lars Kober, Finn Gustafsson, Jacob E. Moller, Morten Schou, Jesper Jensen
Summary: This study aimed to investigate the early effect of empagliflozin on erythropoiesis and iron metabolism in patients with heart failure with reduced ejection fraction. The results showed that empagliflozin increased erythropoiesis and enhanced early iron utilization, which may contribute to the cardioprotective properties of empagliflozin.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Karoline Amalie Rask, Tania Deis, Johan Erik Larsson, Kasper Rossing, Finn Gustafsson
Summary: Hyponatremia is associated with worse outcomes in patients with chronic heart failure and reduced ejection fraction (HFrEF). This study aimed to investigate the potential association between hemodynamic derangement and hyponatremia in HFrEF patients. The study included 502 HFrEF patients who underwent a right heart catheterization. The results showed that lower sodium levels were associated with more deranged invasive hemodynamic measurements and hyponatremia was significantly associated with a composite endpoint in these patients.
Editorial Material
Cardiac & Cardiovascular Systems
Hoong Sern Lim, Finn Gustafsson
CIRCULATION-HEART FAILURE
(2023)
Letter
Medical Laboratory Technology
Morten Baltzer Houlind, Esben Iversen, Viktor Rotbain Curovic, Morten Buss Jorgensen, Aino Andersen, Finn Gustafsson, Laerke Marie Sidenius Nelson, Michael Perch, Morten Damgaard, Frederik Persson, Bo Feldt-Rasmussen, Ove Andersen, Trine Meldgaard Lund, Mads Hornum
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Multidisciplinary Sciences
Morten H. Malmborg, Ali Assad Turky Al-Kahwa, Lars D. Kober, Christian K. Torp-Pedersen, Jawad Butt, Deewa Zahir, Christian Tuxen, Mikael Poulsen, Christian Madelaire, Emil Fosbol, Gunnar Gislason, Per Hildebrandt, Charlotte Andersson, Finn Gustafsson, Morten Schou
Summary: This study found that continued follow-up in specialized heart failure clinics did not improve long-term outcomes in HFrEF patients who had already received guideline-directed therapy. There is a need for the development and implementation of new monitoring strategies.
Article
Cardiac & Cardiovascular Systems
Oscar Westin, Jawad H. H. Butt, Steffen Heegaard, Emil L. L. Fosbol, Finn Gustafsson
Summary: This study found no significant association between glaucoma and the future diagnosis of amyloidosis in patients with variant transthyretin amyloidosis (ATTRv) when compared to the general population.
SCANDINAVIAN CARDIOVASCULAR JOURNAL
(2023)
Article
Endocrinology & Metabolism
Mikkel Jurgens, Morten Schou, Philip Hasbak, Andreas Kjaer, Emil Wolsk, Bo Zerahn, Niels H. Brandt-Jacobsen, Peter Gaede, Peter Rossing, Jens Faber, Silvio E. Inzucchi, Finn Gustafsson, Caroline Kistorp
Summary: Empagliflozin has been found to reduce measured glomerular filtration rate (mGFR), estimated plasma volume (PV), and estimated extracellular volume (ECV) in patients with type 2 diabetes (T2D) and high risk of cardiovascular events. The 13-week randomized controlled trial showed a decrease in mGFR, ECV, and PV with the use of the drug.
DIABETES OBESITY & METABOLISM
(2023)
Article
Cardiac & Cardiovascular Systems
Gerhard Poelzl, Johann Altenberger, Josep Comin-Colet, Juan F. Delgado, Francesco Fedele, Martin Jesus Garcia-Gonzalez, Finn Gustafsson, Josep Masip, Zoltan Papp, Stefan Stoerk, Hanno Ulmer, Sarah Maier, Bojan Vrtovec, Gerhard Wikstrom, Endre Zima, Axel Bauer, LeoDOR Investigators
Summary: The LeoDOR trial aimed to investigate the efficacy and safety of intermittent levosimendan therapy in patients with acute heart failure after hospitalization. The results showed that intermittent levosimendan therapy did not improve post-hospitalization clinical stability in patients recently hospitalized with reduced left ventricular ejection fraction.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Antoni Bayes-Genis, Kieran F. Docherty, Mark C. Petrie, James L. Januzzi, Christian Mueller, Lisa Andreson, Biykem Bozkurt, Javed Butler, Ovidiu Chioncel, John G. F. Cleland, Ruxandra Christodorescu, Stefano Del Prato, Finn Gustafsson, Carolyn S. P. Lam, Brenda Moura, Rodica Pop-Busui, Petar Seferovic, Maurizio Volterrani, Muthiah Vaduganathan, Marco Metra, Giuseppe Rosano
Summary: Diagnosing heart failure is often difficult due to non-specific symptoms. This document explores the use of NT-proBNP as a biomarker for diagnosing heart failure in different clinical scenarios. Validated cut-points are provided for ruling in or ruling out acute and de novo heart failure. The concept of 'heart stress' is introduced, and a simple acronym FIND-HF is proposed for early diagnosis of heart failure.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Julie K. K. Vishram-Nielsen, Finn Gustafsson
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
William Herrik Nielsen, Finn Gustafsson, Peter Skov Olsen, Peter Bo Hansen, Kasper Rossing, Nikolaj Bang Lilleor, Peter Hasse Moller-Sorensen, Christian Holdflod Moller
Summary: The use of ex vivo perfusion in heart transplantation allows for a longer out-of-body time and reduced cold ischemic time without adversely affecting safety or early post-transplant outcomes.
SCANDINAVIAN CARDIOVASCULAR JOURNAL
(2023)
Article
Surgery
Rikke E. Mols, Brian B. Logstrup, Istvan Bakos, Erzsebet Horvath-Puho, Bo Christensen, Christoffer T. Witt, Morten Schmidt, Finn Gustafsson, Hans Eiskjaer
Summary: Socioeconomic deprivation may limit access to healthcare, and individual indicators of socioeconomic disadvantage can affect clinical outcomes after heart transplantation. In a population-based study of Danish first-time heart transplant recipients, low education level and low income were associated with poorer prognosis.
TRANSPLANT INTERNATIONAL
(2023)
Article
Public, Environmental & Occupational Health
Hjalte Erichsen Larsen, Uka Wilhjelm Geisler, Finn Gustafsson, Marit Eika Jorgensen, Michael Lynge Pedersen
Summary: Heart Failure (HF) is a significant burden for healthcare worldwide. This study aims to estimate the prevalence of HF and describe the characteristics of patients with HF in Greenland. The overall prevalence was 1.1%, higher among men than women, and highest among men above 84 years. More than half of the patients were obese and/or smokers, and a low prevalence of ischaemic heart disease (IHD) was observed.
INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH
(2023)
